Nonscarring alopecias preserve the follicular opening and may allow regrowth when the underlying process is controlled. Scarring, or cicatricial, alopecias destroy follicles and can cause permanent loss, so identifying active disease and controlling inflammation early can be especially important.
Hair Loss Management in Dermatology: Diagnosis, Treatment and Adherence Challenges
A peer view of how dermatology clinicians diagnose hair loss, choose treatment, escalate care, and manage adherence and expectations when response is uncertain.
Audience: Dermatology clinicians
Countries: 4
Completion Rate: 76.6%
SGID: 9011815
-Hero findings
– Quick Read — Key Findings
65.4%
Pattern hair loss leads the clinical starting point
Androgenetic alopecia is the dominant phenotype in this respondent group.
47.1%
Biopsy still changes the picture
Almost half say scalp biopsy findings can alter the diagnostic workup.
66.7%
Topical minoxidil remains the default first move
It is chosen far more often than the other listed first-line options.
49.0%
Adherence is the leading reason treatment fails early
It outranks insufficient duration, disease progression, and incorrect diagnosis.
54.9%
Active scarring alopecia changes treatment strategy most
Scarring disease prompts a greater pathway shift than the other listed subgroups.
33.3%
Regenerative follicle therapies edge ahead
It narrowly leads novel follicle-targeted therapies and JAK inhibitors for alopecia areata.
When hair loss persists, what should change next?
Hair-loss care gets harder when the phenotype changes.
Hair-loss management begins with phenotype, but clinicians must also decide when shedding, inflammation, scarring, or treatment response suggests a different pathway.
Across the survey, androgenetic alopecia dominates the starting point, while trichoscopy, biopsy, treatment escalation, adherence, and expectations repeatedly determine what happens next.
Androgenetic alopecia leads, but the pathway cannot stay phenotype-blind.
65.4% say androgenetic alopecia most often drives their clinical evaluation, compared with 19.2% for telogen effluvium, 11.5% for alopecia areata, and 3.8% for scarring alopecia.
Pattern hair loss may dominate routine practice, but the pathway still needs checkpoints for alternative or irreversible disease, especially when scarring features can shift the goal from regrowth to disease control.
Trichoscopy and biopsy are the key diagnostic pivots.
54.9% select trichoscopy abnormalities and 47.1% scalp biopsy findings among the findings that most strongly change their workup. A positive hair-pull test follows at 39.2%, while hormonal or nutritional abnormalities are selected by 21.6%.
The ranking suggests hair- and scalp-specific evidence is more likely to redirect the workup than systemic abnormalities alone. The key decision is when visual pattern recognition is no longer enough.
Topical minoxidil starts the pathway, but persistent loss drives escalation.
66.7% typically initiate topical minoxidil first. Oral minoxidil follows at 21.6%, intralesional corticosteroids at 9.8%, and antiandrogen therapy at 2.0%.
When hair loss persists, 54.9% choose pharmacotherapy escalation as the primary next step, while 25.5% perform a scalp biopsy; 9.8% repeat trichoscopy first and 9.8% add a procedural treatment. The split shows that persistence can trigger either more treatment or a return to diagnosis.
Early treatment failure is often an adherence problem.
49.0% identify poor treatment adherence as the most common driver of initial treatment failure. Insufficient treatment duration follows at 23.5%, progressive disease activity at 19.6%, and incorrect diagnosis at 7.8%.
Poor adherence leads early treatment failure, with insufficient duration next. The 62.7% expectation barrier reinforces the need to make the treatment timeline clear from the start, so a reasonable plan is not abandoned before it can be assessed.
Long-term success needs more than one endpoint.
Objective density improvement is selected by 51.0% as supporting long-term therapy, but reduced shedding is close behind at 45.1%. Patient-reported benefit is selected by 39.2%, and stable disease activity by 35.3%.
No single endpoint dominates. Density, shedding, patient-reported benefit, and disease stability all matter, allowing success to be matched to the diagnosis and treatment goal.
Active scarring alopecia changes the pathway most.
54.9% say active scarring alopecia most changes their treatment pathway, compared with 23.5% for severe alopecia areata, 15.7% for refractory androgenetic alopecia, and 5.9% for female-pattern hair loss.
This is where treatment goals change most sharply: active scarring disease can move care from regrowth toward controlling progression and preserving remaining follicles. Open-ended responses also describe overlap, unclear histology, and treatment resistance.
Hair-loss care depends on aligning diagnosis, treatment time, and expectations.
The survey shows a connected pathway: phenotype guides the start, trichoscopy and biopsy clarify uncertainty, escalation follows persistent loss, and adherence determines whether a reasonable plan gets a fair trial.
Unrealistic expectations emerge as the largest management barrier, reinforcing the need to define success early, whether that means regrowth, reduced shedding, or disease stability. New therapies may expand options, but outcomes will still depend on recognizing pathway changes and keeping patients engaged long enough to assess response.
Oncology & Hematology
9Hospital Administration
8Endocrinology, Diabetes & Metabolism
8Diabetes, Weight & Metabolic Health
7Primary Care & Family Medicine
7Dermatology
7Ophthalmology
7Pharmacy
7Gastroenterology & Hepatology
7Dentistry & Oral Health
6Surgery & Procedural Care
6Pediatrics
6Nurses, NPs & Physician Assistants
6Neurology
6Laboratory & Diagnostics
5
Cardiology
4Brain, Nerves & Mental Health
3Optometry & Optical Care
3Skin & Aesthetic Care
3Radiology & Imaging
3Cancer Care
1
You have read the summary
Go deeper into the findings.
Be part of what comes next.
Explore the complete findings in the full report, or join MDForLives to contribute your perspectives to future healthcare research.
Frequently asked questions
Common questions on trichoscopy, scalp biopsy, minoxidil, scarring alopecia, and alopecia areata.
What is trichoscopy and how is it used in hair-loss diagnosis?
Trichoscopy is dermoscopic examination of the hair and scalp. It helps dermatologists identify patterns that may not be obvious on visual inspection alone and can support differentiation among common scarring and nonscarring alopecias. It is usually interpreted alongside history, examination, hair-pull findings, and other tests when needed.
When is a scalp biopsy used for hair loss?
A scalp biopsy is generally considered when the diagnosis remains uncertain, when scarring alopecia is suspected, or when clinical and trichoscopic findings do not fully explain the pattern of hair loss. The biopsy site and technique matter because active margins can be more informative than end-stage scarred areas.
Is topical minoxidil a common treatment for androgenetic alopecia?
Yes. Topical minoxidil remains a widely used treatment for pattern hair loss. Response varies, treatment is usually continued long term if effective, and patients need realistic counseling that visible improvement takes time rather than days or a few weeks.
How long can minoxidil take to show visible results?
For pattern hair loss, visible improvement may take several months. American Academy of Dermatology patient guidance notes that topical minoxidil can take about six to twelve months to show how well it is working, which makes adherence and expectation-setting important early in treatment.
How are scarring and nonscarring alopecia different clinically?
Are JAK inhibitors now used for alopecia areata?
Yes, for selected patients with severe alopecia areata. In the United States, oral JAK-pathway therapies have received FDA approvals for severe alopecia areata in adults, and some options also include adolescents. Treatment choice depends on disease severity, age, comorbidities, risks, monitoring needs, and local regulatory status.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.


